NCT05841238CompletedPhase 1
A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants
A Multiple Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Tablet and Capsule Formulations of LY3502970 in Healthy Overweight and Obese Participants
Source: ClinicalTrials.gov · Last updated 10 Jul 2026
Brief summary (registry, in English)
The main purpose of this study is to evaluate how much LY3502970 gets into the bloodstream and how long it takes the body to eliminate when administered orally as tablet and capsule formulations along with effect of food on LY3502970 in healthy overweight and obese participants. The study will also evaluate the safety and tolerability of LY3502970 in these participants. The study is conducted in two parts (part A and B) and will last up to 135 days including the screening period.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 52 (actual)
- First submitted
- 24 Apr 2023
- Start date
- 26 Apr 2023
- Primary completion date
- 14 Sept 2023
- Lead sponsor
- Eli Lilly and Company
- Diseases
- Obesity
- NCT number
- NCT05841238
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 52
- From 26 Apr 2023 to the primary completion date, 14 Sept 2023
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have undergone bariatric surgery (for example: Lap-Band, Gastric Bypass)
- Have significant previous or current history of comorbidities capable of significantly altering the absorption, metabolism, or elimination of drug
Other illness
- Obesity induced by other endocrine disorders, such as Cushing's syndrome or Prader-Willi syndrome
- Known self or family history (first-degree relative) of multiple endocrine neoplasia type 2A or type 2B, thyroid C-cell hyperplasia, or any form of thyroid cancer
- Have significant history of or currently have Major Depressive Disorder or psychiatric disorder within the last 2 years
Lab values
- Have any type of diabetes with hemoglobin A1c (HbA1c) level of 6.5% or greater or a fasting blood sugar over 120 milligram per deciliter (mg/dL)
Other
- Have known clinically significant gastric emptying abnormality
Who the study is looking for
- Male or female participants who are overtly healthy as determined by medical evaluation
- Participants with body mass index (BMI) of 27.0 kilograms per meter squared (kg/m²) or more
- Participants with a stable body weight, with 5% or less body weight gain or loss
Age in the registry: 18 years to 70 years · Sex: All · Accepts healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Labcorp Clinical Research LP Coordinator of this site? Confirm its status | Dallas | United States | Unknown status |
| LabCorp CRU, Inc. Coordinator of this site? Confirm its status | Daytona Beach | United States | Unknown status |
| LabCorp CRU, Inc. Coordinator of this site? Confirm its status | Madison | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.